• NORTH CAROLINA SOCIETY OF GASTROENTEROLOGY
  • 704.376.3688
  • sbuchanan@meckmed.org
NCSGlogo-300NCSGlogo-only-150NCSGlogo-300NCSGlogo-300
  • Home
  • Events and Education
  • Research
  • About NCSG
    • Board of Directors
    • Board Meetings
    • Grants
    • Partners
    • NCSG Bylaws
JOIN or RENEW HERE
✕
Categories
  • Nonalcoholic Steatohepatitis
Tags
  • Nonalcoholic Steatohepatitis (NASH)
Study title Madrigal-11: A Phase 3, Multinational, Double-Blind, Randomized,Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With NASH and Fibrosis to Resolve NASH and reduce Progression to Cirrhosis
Disease or condition NAFLD/NASH with Fibrosis
Study type Interventional (Clinical Trial)
Intervention/treatment MGL-3196 (Resmetirom) or Placebo
Phase 3
Study site Duke University
Study location Durham, NC
Principal investigator Anna Mae Diehl, MD
Study coordinator Magdi Elgasim, Phone:  919-684-9019 Email: magdi.elgasim@duke.edu
Phone contact (919) 613-8802
Clinicaltrials.gov link https://clinicaltrials.gov/ct2/show/NCT03900429

ADDRESS


1112 Harding Place
Suite 100
Charlotte NC 28204

Fax: 704.376.3173

LINKS


Home
Education
Events
Research
JOIN NOW

CONTACT


704.376.3688
sbuchanan@meckmed.org

Copyright: North Carolina Society of Gastroenterology (NCSG)
JOIN or RENEW HERE